News

Novo Nordisk A/S (NYSE:NVO) ranks among the best set-it-and-forget-it stocks to buy. Novo Nordisk A/S (NYSE:NVO) announced on ...
Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...
Novo Nordisk A/S’ (NYSE:NVO) executives allegedly ignored internal warnings that the company was unprepared to launch its ...
Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the ...
Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ...
While Novo Nordisk stock has underperformed since my Strong Buy rating four months ago, the long-term investment thesis ...
The partnership helps Novo capture patients who have been using compounded versions of the medicine, while allowing ...
Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for ...
This morning, the Danish pharmaceutical giant Novo Nordisk announced the abrupt end of its brief partnership with telehealth ...
Wegovy (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership.
Novo Nordisk said Hims & Hers has “failed to adhere to the law which prohibits mass sales of compounded drugs” under the ...
Novo Nordisk cut ties with Hims & Hers, accusing the telehealth firm of promoting Wegovy copycat versions of the weight-loss ...